glp 1 drugs novo nordisk EMA will monitor suicide risk in Nordisk's GLP-1 products Ozempic maker Novo Nordisk is
Description
The FDA approval of Wegovy pill is based on the results from the OASIS 4 Phase 3 clinical trial, which was a 64-week medical study that included 307 adults with obesity or overweight with one or more weight-related comorbidities, without diabetes
The first RCT, focusing on exenatide, reported no significant reduction in alcohol consumption over 24 weeks
doi: 10.1139/cjpp-2023-0464 Kunik E, Dudkowiak R, Adamiec R, Poniewierka E
Your primary care provider or a specialist can help you weigh the pros and cons of GLP-1s
